Advertisement

Advertisement

Most Read Stories
Follow-up of Adjuvant Paclitaxel and Trastuzumab in Small HER2-Positive Breast Tumors
'Oral Cryotherapy' for Patients Undergoing Oxaliplatin-Based Chemotherapy
KEYNOTE-158: Pembrolizumab in Previously Treated Advanced Cervical Cancer
FDA Approves Pembrolizumab Plus Axitinib for First-Line Treatment of Advanced Renal Cell Carcinoma
Lenvatinib in Recurrent or Metastatic Adenoid Cystic Carcinoma
Fallopian Tube Removal May Protect Premenopausal Women at High Risk for Ovarian Cancer From Some Surgical Side Effects
KEYNOTE-042: Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic NSCLC With PD-L1 Expression ≥ 1%
Complementary and Alternative Medicine Use in Patients With Cancer
Primary Surgery Outcomes in MRI-Based ‘Good-Prognosis’ Rectal Cancer
When Can Patients With Gleason 6 Prostate Cancer Safely Undergo Active Surveillance?
ASCO and ASH Release Update to Clinical Practice Guidelines for Use of Erythropoiesis-Stimulating Agents
Addition of Radiotherapy After Breast-Conserving Surgery Based on Level of Tumor-Infiltrating Lymphocytes
Perioperative Therapy With FLOT vs ECF/ECX in Locally Advanced Gastric Adenocarcinoma
FDA Pipeline: Designations for Myelodysplastic Syndromes, Triple-Negative Breast Cancer, AML, and EBV-Associated Cancers
Treatment of Patients With Imminently Fatal de Novo Metastatic Cancer
How I Work up the Patient with Thrombocytosis
Niraparib in Late-Line Treatment of Ovarian Cancer
Front-Line Dose-Adjusted EPOCH-R vs R-CHOP in Diffuse Large B-Cell Lymphoma
Addition of Bortezomib to R-CHOP in DLBCL Subtypes Identified With Gene-Expression Profiling
Report Examines Shortages of Oncologists, Variation in Cancer Rates

Advertisement

Advertisement



;
Advertisement